GoKawiilModerna said the FDA’s Vaccines and Related Biological Products Advisory Committee voted unanimously that the benefits of the vaccine, mRNA-1010, exceed the risks for the prevention of flu in adults 50 through 64 years old, and in adults 65 years of age and older.
FDA Votes in Favor of Benefit-Risk Profile for Moderna’s Flu Vaccine
Why This Matters
The FDA's positive assessment of Moderna's mRNA-1010 flu vaccine marks a significant milestone in the adoption of mRNA technology for seasonal flu prevention, potentially transforming how flu vaccines are developed and administered. This approval could lead to more effective and adaptable vaccines, benefiting both consumers and the broader healthcare industry. As the first mRNA flu vaccine to receive such endorsement, it paves the way for future innovations in infectious disease prevention.
Key Takeaways
- FDA committee unanimously supports Moderna’s flu vaccine for older adults.
- mRNA technology is now being validated for seasonal flu prevention.
- This approval may accelerate the development of more effective vaccines in the future.
Get alerts for these topics